In contrast, the therapeutic potentials of ERβ agonists for the treatment of other pathologies such as prostate cancer or cardiovascular diseases attract researchers to develop selective ERβ agonists as safe and efficacious drugs. This evidence concerns the gene ESR2 and prostate cancer.